Costs and resource utilization for diagnosis and treatment during the initial year in a european inflammatory bowel disease inception cohort: An ECCO-EpiCom study

Johan Burisch, Hillel Vardi, Natalia Pedersen, Marko Brinar, Silvja Cukovic-Cavka, Ioannis Kaimakliotis, Dana Duricova, Martin Bortlik, Olga Shonová, Ida Vind, Søren Avnstrøm, Niels Thorsgaard, Susanne Krabbe, Vibeke Andersen, Jens F. Dahlerup, Jens Kjeldsen, Riina Salupere, Jóngero Olsen, Kári R. Nielsen, Pia ManninenPekka Collin, Konstantinnos H. Katsanos, Epameinondas V. Tsianos, Karin Ladefoged, L. Lakatos, Yvonne Bailey, Colm O'Morain, Doron Schwartz, Guido Lupinacci, Angelo De Padova, Laimas Jonaitis, Limas Kupcinskas, Svetlana Turcan, Louisa Barros, Fernando Magro, Daniela Lazar, Adrian Goldis, Inna Nikulina, Elena Belousova, Alberto Fernandez, Juan R. Pineda, Sven Almer, Jonas Halfvarson, Her Hsin Tsai, Shaji Sebastian, Michael Friger, Dan Greenberg, P. Lakatos, Ebbe Langholz, Selwyn Odes, Pia Munkholm

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe. Methods: The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (€) using the Danish Health Costs Register. Results: One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was €5,408,174 (investigations: €2,042,990 [38%], surgery: €1,427,648 [26%], biologicals: €781,089 [14%], and standard treatment: €1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations €1803 (€2160) (P = 0.44), surgery €11,489 (€13,973) (P = 0.14), standard treatment €1027 (€824) (P = 0.51), and biologicals €7376 (€8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations €1189 (€1518) (P <0.01), surgery €18,414 (€12,395) (P = 0.18), standard treatment €896 (€798) (P <0.05), and biologicals €5681 (€72) (P = 0.51). Conclusions: In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15% of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.

Original languageEnglish
Pages (from-to)121-131
Number of pages11
JournalInflammatory Bowel Diseases
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Inflammatory Bowel Diseases
Costs and Cost Analysis
Health Expenditures
Health Care Costs
Eastern Europe
Ulcerative Colitis
Crohn Disease
Therapeutics
Biological Factors
Cost-Benefit Analysis
Population

Keywords

  • Crohn's disease
  • Economics of IBD therapies
  • Epidemiology
  • Outcomes research
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Costs and resource utilization for diagnosis and treatment during the initial year in a european inflammatory bowel disease inception cohort : An ECCO-EpiCom study. / Burisch, Johan; Vardi, Hillel; Pedersen, Natalia; Brinar, Marko; Cukovic-Cavka, Silvja; Kaimakliotis, Ioannis; Duricova, Dana; Bortlik, Martin; Shonová, Olga; Vind, Ida; Avnstrøm, Søren; Thorsgaard, Niels; Krabbe, Susanne; Andersen, Vibeke; Dahlerup, Jens F.; Kjeldsen, Jens; Salupere, Riina; Olsen, Jóngero; Nielsen, Kári R.; Manninen, Pia; Collin, Pekka; Katsanos, Konstantinnos H.; Tsianos, Epameinondas V.; Ladefoged, Karin; Lakatos, L.; Bailey, Yvonne; O'Morain, Colm; Schwartz, Doron; Lupinacci, Guido; De Padova, Angelo; Jonaitis, Laimas; Kupcinskas, Limas; Turcan, Svetlana; Barros, Louisa; Magro, Fernando; Lazar, Daniela; Goldis, Adrian; Nikulina, Inna; Belousova, Elena; Fernandez, Alberto; Pineda, Juan R.; Almer, Sven; Halfvarson, Jonas; Tsai, Her Hsin; Sebastian, Shaji; Friger, Michael; Greenberg, Dan; Lakatos, P.; Langholz, Ebbe; Odes, Selwyn; Munkholm, Pia.

In: Inflammatory Bowel Diseases, Vol. 21, No. 1, 01.01.2015, p. 121-131.

Research output: Contribution to journalArticle

Burisch, J, Vardi, H, Pedersen, N, Brinar, M, Cukovic-Cavka, S, Kaimakliotis, I, Duricova, D, Bortlik, M, Shonová, O, Vind, I, Avnstrøm, S, Thorsgaard, N, Krabbe, S, Andersen, V, Dahlerup, JF, Kjeldsen, J, Salupere, R, Olsen, J, Nielsen, KR, Manninen, P, Collin, P, Katsanos, KH, Tsianos, EV, Ladefoged, K, Lakatos, L, Bailey, Y, O'Morain, C, Schwartz, D, Lupinacci, G, De Padova, A, Jonaitis, L, Kupcinskas, L, Turcan, S, Barros, L, Magro, F, Lazar, D, Goldis, A, Nikulina, I, Belousova, E, Fernandez, A, Pineda, JR, Almer, S, Halfvarson, J, Tsai, HH, Sebastian, S, Friger, M, Greenberg, D, Lakatos, P, Langholz, E, Odes, S & Munkholm, P 2015, 'Costs and resource utilization for diagnosis and treatment during the initial year in a european inflammatory bowel disease inception cohort: An ECCO-EpiCom study', Inflammatory Bowel Diseases, vol. 21, no. 1, pp. 121-131. https://doi.org/10.1097/MIB.0000000000000250
Burisch, Johan ; Vardi, Hillel ; Pedersen, Natalia ; Brinar, Marko ; Cukovic-Cavka, Silvja ; Kaimakliotis, Ioannis ; Duricova, Dana ; Bortlik, Martin ; Shonová, Olga ; Vind, Ida ; Avnstrøm, Søren ; Thorsgaard, Niels ; Krabbe, Susanne ; Andersen, Vibeke ; Dahlerup, Jens F. ; Kjeldsen, Jens ; Salupere, Riina ; Olsen, Jóngero ; Nielsen, Kári R. ; Manninen, Pia ; Collin, Pekka ; Katsanos, Konstantinnos H. ; Tsianos, Epameinondas V. ; Ladefoged, Karin ; Lakatos, L. ; Bailey, Yvonne ; O'Morain, Colm ; Schwartz, Doron ; Lupinacci, Guido ; De Padova, Angelo ; Jonaitis, Laimas ; Kupcinskas, Limas ; Turcan, Svetlana ; Barros, Louisa ; Magro, Fernando ; Lazar, Daniela ; Goldis, Adrian ; Nikulina, Inna ; Belousova, Elena ; Fernandez, Alberto ; Pineda, Juan R. ; Almer, Sven ; Halfvarson, Jonas ; Tsai, Her Hsin ; Sebastian, Shaji ; Friger, Michael ; Greenberg, Dan ; Lakatos, P. ; Langholz, Ebbe ; Odes, Selwyn ; Munkholm, Pia. / Costs and resource utilization for diagnosis and treatment during the initial year in a european inflammatory bowel disease inception cohort : An ECCO-EpiCom study. In: Inflammatory Bowel Diseases. 2015 ; Vol. 21, No. 1. pp. 121-131.
@article{9c83b285b9fa423faa2e9f3ed3626b7f,
title = "Costs and resource utilization for diagnosis and treatment during the initial year in a european inflammatory bowel disease inception cohort: An ECCO-EpiCom study",
abstract = "Background: No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe. Methods: The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (€) using the Danish Health Costs Register. Results: One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was €5,408,174 (investigations: €2,042,990 [38{\%}], surgery: €1,427,648 [26{\%}], biologicals: €781,089 [14{\%}], and standard treatment: €1,156,520 [22{\%})]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations €1803 (€2160) (P = 0.44), surgery €11,489 (€13,973) (P = 0.14), standard treatment €1027 (€824) (P = 0.51), and biologicals €7376 (€8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations €1189 (€1518) (P <0.01), surgery €18,414 (€12,395) (P = 0.18), standard treatment €896 (€798) (P <0.05), and biologicals €5681 (€72) (P = 0.51). Conclusions: In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15{\%} of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.",
keywords = "Crohn's disease, Economics of IBD therapies, Epidemiology, Outcomes research, Ulcerative colitis",
author = "Johan Burisch and Hillel Vardi and Natalia Pedersen and Marko Brinar and Silvja Cukovic-Cavka and Ioannis Kaimakliotis and Dana Duricova and Martin Bortlik and Olga Shonov{\'a} and Ida Vind and S{\o}ren Avnstr{\o}m and Niels Thorsgaard and Susanne Krabbe and Vibeke Andersen and Dahlerup, {Jens F.} and Jens Kjeldsen and Riina Salupere and J{\'o}ngero Olsen and Nielsen, {K{\'a}ri R.} and Pia Manninen and Pekka Collin and Katsanos, {Konstantinnos H.} and Tsianos, {Epameinondas V.} and Karin Ladefoged and L. Lakatos and Yvonne Bailey and Colm O'Morain and Doron Schwartz and Guido Lupinacci and {De Padova}, Angelo and Laimas Jonaitis and Limas Kupcinskas and Svetlana Turcan and Louisa Barros and Fernando Magro and Daniela Lazar and Adrian Goldis and Inna Nikulina and Elena Belousova and Alberto Fernandez and Pineda, {Juan R.} and Sven Almer and Jonas Halfvarson and Tsai, {Her Hsin} and Shaji Sebastian and Michael Friger and Dan Greenberg and P. Lakatos and Ebbe Langholz and Selwyn Odes and Pia Munkholm",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/MIB.0000000000000250",
language = "English",
volume = "21",
pages = "121--131",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Costs and resource utilization for diagnosis and treatment during the initial year in a european inflammatory bowel disease inception cohort

T2 - An ECCO-EpiCom study

AU - Burisch, Johan

AU - Vardi, Hillel

AU - Pedersen, Natalia

AU - Brinar, Marko

AU - Cukovic-Cavka, Silvja

AU - Kaimakliotis, Ioannis

AU - Duricova, Dana

AU - Bortlik, Martin

AU - Shonová, Olga

AU - Vind, Ida

AU - Avnstrøm, Søren

AU - Thorsgaard, Niels

AU - Krabbe, Susanne

AU - Andersen, Vibeke

AU - Dahlerup, Jens F.

AU - Kjeldsen, Jens

AU - Salupere, Riina

AU - Olsen, Jóngero

AU - Nielsen, Kári R.

AU - Manninen, Pia

AU - Collin, Pekka

AU - Katsanos, Konstantinnos H.

AU - Tsianos, Epameinondas V.

AU - Ladefoged, Karin

AU - Lakatos, L.

AU - Bailey, Yvonne

AU - O'Morain, Colm

AU - Schwartz, Doron

AU - Lupinacci, Guido

AU - De Padova, Angelo

AU - Jonaitis, Laimas

AU - Kupcinskas, Limas

AU - Turcan, Svetlana

AU - Barros, Louisa

AU - Magro, Fernando

AU - Lazar, Daniela

AU - Goldis, Adrian

AU - Nikulina, Inna

AU - Belousova, Elena

AU - Fernandez, Alberto

AU - Pineda, Juan R.

AU - Almer, Sven

AU - Halfvarson, Jonas

AU - Tsai, Her Hsin

AU - Sebastian, Shaji

AU - Friger, Michael

AU - Greenberg, Dan

AU - Lakatos, P.

AU - Langholz, Ebbe

AU - Odes, Selwyn

AU - Munkholm, Pia

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe. Methods: The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (€) using the Danish Health Costs Register. Results: One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was €5,408,174 (investigations: €2,042,990 [38%], surgery: €1,427,648 [26%], biologicals: €781,089 [14%], and standard treatment: €1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations €1803 (€2160) (P = 0.44), surgery €11,489 (€13,973) (P = 0.14), standard treatment €1027 (€824) (P = 0.51), and biologicals €7376 (€8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations €1189 (€1518) (P <0.01), surgery €18,414 (€12,395) (P = 0.18), standard treatment €896 (€798) (P <0.05), and biologicals €5681 (€72) (P = 0.51). Conclusions: In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15% of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.

AB - Background: No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe. Methods: The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (€) using the Danish Health Costs Register. Results: One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was €5,408,174 (investigations: €2,042,990 [38%], surgery: €1,427,648 [26%], biologicals: €781,089 [14%], and standard treatment: €1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations €1803 (€2160) (P = 0.44), surgery €11,489 (€13,973) (P = 0.14), standard treatment €1027 (€824) (P = 0.51), and biologicals €7376 (€8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations €1189 (€1518) (P <0.01), surgery €18,414 (€12,395) (P = 0.18), standard treatment €896 (€798) (P <0.05), and biologicals €5681 (€72) (P = 0.51). Conclusions: In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15% of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.

KW - Crohn's disease

KW - Economics of IBD therapies

KW - Epidemiology

KW - Outcomes research

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84925827444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925827444&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000000250

DO - 10.1097/MIB.0000000000000250

M3 - Article

C2 - 25437816

AN - SCOPUS:84925827444

VL - 21

SP - 121

EP - 131

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 1

ER -